Welcome to our dedicated page for Lobe Sciences news (Ticker: LOBEF), a resource for investors and traders seeking the latest updates and insights on Lobe Sciences stock.
Lobe Sciences Ltd. (OTCQB: LOBEF) generates news primarily as a clinical-stage biopharmaceutical company advancing therapies for diseases with significant unmet medical needs. The company’s disclosures highlight programs in rare neurological and hematological conditions, including chronic cluster headache and sickle cell disease, advanced through its subsidiaries Cynaptec Pharmaceuticals, Inc. and Altemia, Inc.
News updates for Lobe Sciences often cover developments in its lead CNS therapeutic candidate L-130 (also referred to as Conjugated Psilocin™ or psilocin mucate), which is being developed by majority-owned Cynaptec for chronic cluster headache and potential additional CNS indications under strategic review. Announcements have described completion of a Phase 1a study in healthy volunteers, ongoing work aligned with U.S. FDA Pre-IND guidance, and financing transactions at the subsidiary level intended to support further development.
Investors and followers of LOBEF can also expect coverage of Altemia, Inc.’s work on S-100, an early-stage therapeutic candidate for sickle cell disease, and a proprietary medical food in early-stage distribution aimed at addressing nutritional deficiencies commonly observed in patients with sickle cell disease. Company news has discussed how Lobe prioritizes S-100 within its sickle cell program and maintains limited commercialization efforts while assessing reimbursement pathways.
Lobe Sciences’ news flow additionally includes corporate and capital markets updates, such as private placements, debt settlements through equity issuance, leadership transition, Board renewal, and the appointment of new directors with experience in corporate governance, securities law, and international pharmaceutical business development. The company also reports on participation in industry conferences and patient-focused events related to cluster headache and other underserved conditions. Readers interested in LOBEF can use this news page to follow the company’s clinical progress, financing activities, governance developments, and strategic initiatives as disclosed in its official releases.
Lobe Sciences (OTCQB:LOBEF) engaged Massive Intelligence Pty Ltd for investor relations and corporate communications under a letter dated April 15, 2026.
The initial engagement is for three months from April 15, 2026 for a total cash retainer of US$11,800; an optional six-month renewal would add US$31,500. No securities will be issued in connection with the engagement.
Lobe Sciences (OTCQB:LOBEF) closed a non-brokered private placement of 14,615,384 common shares at $0.065 per share for aggregate gross proceeds of approximately $950,000 on April 20, 2026.
Proceeds will fund working capital, advance the S-100 drug candidate for sickle cell disease, and provide capital to subsidiary Applied Lipid Technologies to support development toward human clinical trials; the company has procured required active pharmaceutical ingredient. Securities are subject to a four-month Canadian hold period and are not registered in the United States.
Lobe Sciences (OTCQB:LOBEF) announced a non-brokered private placement of 14,615,384 common shares at $0.065 per share for aggregate gross proceeds of approximately $950,000 on April 10–11, 2026.
The company said proceeds will fund working capital and general corporate expenses; the placement is subject to regulatory approvals, a four-month Canadian hold period, and securities are not registered for sale in the United States.
Lobe Sciences (OTCQB:LOBEF) reported a materially improved financial position as of March 25, 2026. Liabilities fell ~81% from $2.35M to $0.44M; cash rose from $0.24M to $5.99M; net working capital improved by $6.1M to $4.05M; outstanding warrants fell ~70% to ~13M. The company adopted a subsidiary-based, capital-efficient model and sold a 34% interest in Cynaptec to strengthen runway and reduce dilution risk.
Management converted most convertible notes into equity on favorable terms and noted the recent audit omitted a going-concern explanatory paragraph.
Lobe Sciences (OTCQB:LOBEF, CSE:LOBE) announced the promotion of Mr. Mirza Rahimani to Chief Financial Officer, effective March 2, 2026. Mr. Rahimani joined the company December 1, 2025 as a financial advisor and brings over 15 years of experience in accounting, financings, M&A and public-company reporting under IFRS and US GAAP.
He succeeds Mr. Yong Yao, who previously served as CFO through an arrangement with Century Biolabs. The change is presented as part of management alignment to support strategic transactions and regulatory compliance.
Lobe Sciences (OTCQB:LOBEF) announced that CEO Dr. Frederick D. Sancilio will be in Miami, Florida during the Jefferies and Leerink Healthcare Conferences on March 2026 and is available for investor and partner meetings.
The company advances preclinical and early-stage therapeutic assets via focused subsidiaries and is currently progressing two patented programs: L-130 for chronic cluster headache and S-100 for sickle cell disease, with additional programs under evaluation in substance use disorder and other neurological indications.
Lobe Sciences (OTCQB:LOBEF) reported Q1 fiscal 2026 results for the quarter ended November 30, 2025, highlighting increased R&D activity and maintained liquidity. Cash was $5.99M, short-term investments $1.03M, and net working capital $4.05M. R&D rose to $982,087 as L-130 preclinical and regulatory work advanced; net loss was $1.31M. The company reiterated progress via its 64% subsidiary Cynaptec (L-130) and early-stage S-100 program, while noting commercialization and reimbursement uncertainty for a medical food effort in Georgia.
Lobe Sciences (OTCQB:LOBEF) appointed Mr. Nick Karakochuk to its Board of Directors effective January 13, 2026, to bolster governance and capital markets expertise as the company builds on fiscal 2025 momentum.
Mr. Karakochuk is a corporate and securities lawyer focused on mergers and acquisitions, public and private financings, corporate reorganizations, and exchange and securities compliance. In connection with his appointment he was granted 3,500,000 restricted share units under the company's equity incentive plan.
Lobe Sciences (OTCQB:LOBEF) reported audited FY2025 results and an operational update following a leadership transition. Key balance-sheet improvements include cash of $5,854,118, a working capital surplus of $5,163,526, and short-term investments of $1,686,688 as of August 31, 2025. The current portion of convertible notes was eliminated and derivative liability fell to $205,105. FY2025 net loss attributable to the parent was $4,861,611 (loss per share $0.03). The company moved its L-130 program into subsidiary Cynaptec and completed a subsidiary financing that raised $8.46 million at a $22.56 million post-money valuation while retaining 64% ownership. Management says the changes reduce liquidity risk and focus development on two core programs for FY2026.
Lobe Sciences (OTCQB:LOBEF) reported audited FY2025 results and outlined a strategic transformation after a late‑2024 leadership and board change. The company strengthened liquidity: cash $5,854,118, short‑term investments $1,686,688, and working capital $5,163,526 as of August 31, 2025. FY2025 net loss attributable to parent was $4,861,611 (loss per share $0.03). Management moved its lead program L‑130 into subsidiary Cynaptec, which completed a $8,460,000 financing at a $22,560,000 post‑money valuation, leaving Lobe with a 64% stake. Company emphasized reduced legacy liabilities, improved governance, and focus on L‑130 (cluster headache) and S‑100 (sickle cell disease) while noting commercialization and reimbursement risks for a proprietary medical food.